Immunosuppressive drug therapy – biopharmaceutical challenges and remedies

Abstract

Introduction: The most commonly used immunosuppressive drugs (ISDs) which can prevent rejection of transplanted organs include cyclosporine, tacrolimus, mycophenolate mofetil, sirolimus and everolimus. The clinical efficacy of these drugs is greatly influenced by their in vivo performance. Various pharmacokinetic and toxicological constraints limit their therapeutic activity which is a matter of serious concern.

Areas covered: An extensive review establishes that poor solubility in intestinal milieu; substantial gut metabolism by CYP3A along with simultaneous efflux by P-glycoprotein and significant hepatic first-pass metabolism are all potential hindrances resulting in poor oral absorption of highly lipophilic ISDs. On top of that, toxicities accompanied by ISDs further affect their overall therapeutic efficacy.

Expert opinion: This review discusses various barriers to the efficient absorption of ISDs and the potential formulation strategies for resolving such ambiguities. The article highlights the potential role of lymphatic targeting by means of novel lipid nanocarriers in modifying systemic availability, toxicity and efficacy profiles of ISDs. Finally, the present manuscript discusses that integration of P-glycoprotein and CYP inhibitors in lipid nanocarrier system provides a novel perspective of overcoming the significant barriers that leads to poor bioavailability of ISDs.

Keywords:

• bioavailability
• CYP3A
• immunosuppressive drugs
• in vivo performance
• lipid nanocarriers
• P-glycoprotein efflux

Declaration of interest

This project was financially supported by Indian Council of Medical Research, New Delhi. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Notes

This box summarizes key points contained in the article.